This study is a multi-site clinical trial designed to evaluate how the body absorbs and processes Kaempferol, a naturally occurring compound found in many plant-based foods. The primary purpose of the study is to measure the pharmacokinetics and biological absorption of Kaempferol in healthy adults. Participants will receive Kaempferol and undergo scheduled blood and urine collections over a short study period. These samples will be used to measure Kaempferol levels in the body and to assess safety and tolerability. In addition, selected biological samples will be analyzed to explore molecular changes associated with Kaempferol exposure using advanced laboratory methods. The study will be conducted at multiple research centers in the United States using a standardized protocol to ensure consistency across sites. The information collected will help improve understanding of how Kaempferol is absorbed and metabolized in humans and will support future research and regulatory evaluation.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Maximum plasma concentration (Cmax) of Kaempferol
Timeframe: From dosing on Day 1 through 24 hours after the final dose (Day 8)
Time to maximum plasma concentration (Tmax) of Kaempferol
Timeframe: From dosing on Day 1 through 24 hours after the final dose (Day 8)
Area under the plasma concentration-time curve (AUC) of Kaempferol
Timeframe: From dosing on Day 1 through 24 hours after the final dose (Day 8)
Plasma elimination half-life (t½) of Kaempferol
Timeframe: From dosing on Day 1 through 24 hours after the final dose (Day 8)
Apparent clearance of Kaempferol
Timeframe: From dosing on Day 1 through 24 hours after the final dose (Day 8)
Urinary excretion of Kaempferol and metabolites
Timeframe: From dosing on Day 1 through 24 hours after the final dose (Day 8)